Literature DB >> 32631196

The Public Health Value of Opioid Litigation.

Rebecca L Haffajee1.   

Abstract

Opioid litigation continues a growing public health litigation trend in which governments seek to hold companies responsible for population harms related to their products. The litigation can serve to address gaps in regulatory and legislative policymaking and in market self-regulation pervasive in the prescription opioid domain. Moreover, prior opioid settlements have satisfied civil tort litigation objectives of obtaining compensation for injured parties, deterring harmful behavior, and holding certain opioid manufacturers, distributors and pharmacies accountable for their actions. In this way, opioid litigation represents progress over prior public health litigation campaigns involving tobacco, lead paint, and asbestos, which had more limited tort litigation effects. Although opioid litigation is not a comprehensive solution to the opioid crisis, it can complement other strategies and infuse much needed money, behavior changes, and public accountability for prescription opioid and related harms.

Entities:  

Mesh:

Year:  2020        PMID: 32631196      PMCID: PMC7481928          DOI: 10.1177/1073110520935340

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN: 1073-1105            Impact factor:   1.718


  19 in total

Review 1.  Litigation and public health policy making: the case of tobacco control.

Authors:  P D Jacobson; K E Warner
Journal:  J Health Polit Policy Law       Date:  1999-08       Impact factor: 2.265

2.  Tobacco control in the wake of the 1998 master settlement agreement.

Authors:  Steven A Schroeder
Journal:  N Engl J Med       Date:  2004-01-11       Impact factor: 91.245

3.  Asbestos and the future of mass torts.

Authors:  Michelle J White
Journal:  J Econ Perspect       Date:  2004

Review 4.  The Master Settlement Agreement and its impact on tobacco use 10 years later: lessons for physicians about health policy making.

Authors:  Walter J Jones; Gerard A Silvestri
Journal:  Chest       Date:  2010-03       Impact factor: 9.410

5.  The Tobacco Master Settlement Agreement - Strategic Lessons for Addressing Public Health Problems.

Authors:  Cheryl Healton
Journal:  N Engl J Med       Date:  2018-09-13       Impact factor: 91.245

6.  Drug Companies' Liability for the Opioid Epidemic.

Authors:  Rebecca L Haffajee; Michelle M Mello
Journal:  N Engl J Med       Date:  2017-12-14       Impact factor: 91.245

Review 7.  Opioid epidemic in the United States.

Authors:  Laxmaiah Manchikanti; Standiford Helm; Bert Fellows; Jeffrey W Janata; Vidyasagar Pampati; Jay S Grider; Mark V Boswell
Journal:  Pain Physician       Date:  2012-07       Impact factor: 4.965

8.  Prescription Drug Monitoring Programs - Friend or Folly in Addressing the Opioid-Overdose Crisis?

Authors:  Rebecca L Haffajee
Journal:  N Engl J Med       Date:  2019-08-22       Impact factor: 91.245

9.  The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013.

Authors:  Curtis S Florence; Chao Zhou; Feijun Luo; Likang Xu
Journal:  Med Care       Date:  2016-10       Impact factor: 2.983

10.  Making the Opioid Public Health Emergency Effective.

Authors:  Rebecca L Haffajee; Richard G Frank
Journal:  JAMA Psychiatry       Date:  2018-08-01       Impact factor: 21.596

View more
  2 in total

1.  How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis.

Authors:  Abhimanyu Sud; Matthew Strang; Daniel Z Buchman; Sheryl Spithoff; Ross E G Upshur; Fiona Webster; Quinn Grundy
Journal:  BMJ Open       Date:  2022-07-12       Impact factor: 3.006

2.  Intersecting substance use treatment and harm reduction services: exploring the characteristics and service needs of a community-based sample of people who use drugs.

Authors:  Noa Krawczyk; Sean T Allen; Kristin E Schneider; Keisha Solomon; Hridika Shah; Miles Morris; Samantha J Harris; Susan G Sherman; Brendan Saloner
Journal:  Harm Reduct J       Date:  2022-08-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.